Zydus Lifesciences Management
Management Kriterienprüfungen 3/4
Zydus Lifesciences CEO ist Sharvil Patel , ernannt in Apr 2017, hat eine Amtszeit von 7.58 Jahren. Die jährliche Gesamtvergütung beträgt ₹300.00M , bestehend aus 60% Gehalt und 40% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.001% der Aktien des Unternehmens, im Wert von ₹14.04M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.5 Jahre bzw. 7.3 Jahre.
Wichtige Informationen
Sharvil Patel
Geschäftsführender
₹300.0m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 60.0% |
| Amtszeit als Geschäftsführer | 7.6yrs |
| Eigentum des Geschäftsführers | 0.001% |
| Durchschnittliche Amtszeit des Managements | 6.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 7.3yrs |
Jüngste Management Updates
Recent updates
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹43b |
| Jun 30 2024 | n/a | n/a | ₹42b |
| Mar 31 2024 | ₹300m | ₹180m | ₹38b |
| Dec 31 2023 | n/a | n/a | ₹30b |
| Sep 30 2023 | n/a | n/a | ₹28b |
| Jun 30 2023 | n/a | n/a | ₹25b |
| Mar 31 2023 | ₹263m | ₹180m | ₹20b |
| Dec 31 2022 | n/a | n/a | ₹21b |
| Sep 30 2022 | n/a | n/a | ₹20b |
| Jun 30 2022 | n/a | n/a | ₹22b |
| Mar 31 2022 | ₹200m | ₹180m | ₹22b |
| Dec 31 2021 | n/a | n/a | ₹23b |
| Sep 30 2021 | n/a | n/a | ₹23b |
| Jun 30 2021 | n/a | n/a | ₹23b |
| Mar 31 2021 | ₹263m | ₹180m | ₹22b |
| Dec 31 2020 | n/a | n/a | ₹18b |
| Sep 30 2020 | n/a | n/a | ₹17b |
| Jun 30 2020 | n/a | n/a | ₹13b |
| Mar 31 2020 | ₹250m | ₹247m | ₹12b |
| Dec 31 2019 | n/a | n/a | ₹12b |
| Sep 30 2019 | n/a | n/a | ₹14b |
| Jun 30 2019 | n/a | n/a | ₹17b |
| Mar 31 2019 | ₹250m | ₹248m | ₹18b |
| Dec 31 2018 | n/a | n/a | ₹20b |
| Sep 30 2018 | n/a | n/a | ₹20b |
| Jun 30 2018 | n/a | n/a | ₹21b |
| Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Vergütung im Vergleich zum Markt: SharvilDie Gesamtvergütung ($USD3.55M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD1.10M).
Entschädigung vs. Einkommen: SharvilDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Sharvil Patel (45 yo)
7.6yrs
Amtszeit
₹300,000,000
Vergütung
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| MD & Executive Director | 7.6yrs | ₹300.00m | 0.0015% ₹ 14.0m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 330.4m | |
| President & CEO of America | 1.1yrs | keine Daten | keine Daten | |
| Chief Financial Officer | no data | ₹54.31m | keine Daten | |
| Head of Investor Relations | no data | keine Daten | keine Daten | |
| Company Secretary & Compliance Officer | 5.8yrs | ₹2.09m | keine Daten |
6.5yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrenes Management: ZYDUSLIFEDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.5 ).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| MD & Executive Director | 27.3yrs | ₹300.00m | 0.0015% ₹ 14.0m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 330.4m | |
| Non-Executive Chairman | 29.5yrs | ₹1.20m | 74.98% ₹ 716.0b | |
| Independent Director | 8.5yrs | ₹4.00m | keine Daten | |
| Non-Executive Non-Independent Director | 27.3yrs | ₹4.00m | 0.0012% ₹ 11.1m | |
| Independent Non-Executive Director | 5.9yrs | ₹4.10m | keine Daten | |
| Independent Director | 2yrs | ₹3.50m | keine Daten | |
| Independent Director | 2yrs | ₹3.50m | keine Daten | |
| Independent Director | less than a year | keine Daten | 0.00044% ₹ 4.2m |
7.3yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrener Vorstand: ZYDUSLIFEDie Vorstandsmitglieder gelten als erfahren (7.3 Jahre durchschnittliche Amtszeit).